

Updates in Management of *Clostridioides difficile* Infections

Thalia McCann, PharmD, PGY1 Acute Care Resident, UC Davis Health

Kathie Le, PharmD, BCPS, Senior Clinical Pharmacist UC Davis Health, Associate Professor, UCSF School of Pharmacy

Edited and peer-reviewed by: Haley N. Johnson, PharmD, BCPS, Assistant Professor St. Louis College of Pharmacy at University of Health Sciences and Pharmacy in St. Louis

References:

1. Leffler DA, Lamont JT. Clostridium difficile Infection. Longo DL, ed. N Engl J Med. 2015;372(16):1539-1548. doi:10.1056/NEJMra1403772
2. Guh AY, Mu Y, Winston LG, et al. Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes. N Engl J Med. 2020;382(14):1320-1330. doi:10.1056/NEJMoa1910215
3. Marra AR, Perencevich EN, Nelson RE, et al. Incidence and Outcomes Associated With Clostridium difficile Infections: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020;3(1):e1917597. doi:10.1001/jamanetworkopen.2019.17597
4. Bagdasarian N, Rao K, Malani PN. Diagnosis and Treatment of Clostridium difficile in Adults: A Systematic Review. JAMA. 2015;313(4):398. doi:10.1001/jama.2014.17103
5. McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clinical Infectious Diseases. 2018;66(7):e1-e48. doi:10.1093/cid/cix1085
6. Mikamo H, Tateda K, Yanagihara K, et al. Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan. Journal of Infection and Chemotherapy. 2018;24(9):744-752. doi:10.1016/j.jiac.2018.05.010
7. Guery B, Menichetti F, Anttila VJ, et al. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. The Lancet Infectious Diseases. 2018;18(3):296-307. doi:10.1016/S1473-3099(17)30751-X
8. Johnson S, Lavergne V, Skinner AM, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in

Adults. *Clinical Infectious Diseases*. Published online June 14, 2021:ciab549.
doi:10.1093/cid/ciab549

9. Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with *Clostridium difficile* in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. *The Lancet Infectious Diseases*. 2012;12(4):281-289.
doi:10.1016/S1473-3099(11)70374-7

10. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus Vancomycin for *Clostridium difficile* Infection. *N Engl J Med*. 2011;364(5):422-431. doi:10.1056/NEJMoa0910812

11. Johnson S, Gerding DN. Bezlotoxumab. *Clinical Infectious Diseases*. 2019;68(4):699-704.
doi:10.1093/cid/ciy577

12. Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for Prevention of Recurrent *Clostridium difficile* Infection. *N Engl J Med*. 2017;376(4):305-317.
doi:10.1056/NEJMoa1602615

13. Gerding DN, Kelly CP, Rahav G, et al. Bezlotoxumab for Prevention of Recurrent *Clostridium difficile* Infection in Patients at Increased Risk for Recurrence. *Clinical Infectious Diseases*. 2018;67(5):649-656. doi:10.1093/cid/ciy171

14. Kelly CR, Khoruts A, Staley C, et al. Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent *Clostridium difficile* Infection: A Randomized Trial. *Ann Intern Med*. 2016;165(9):609. doi:10.7326/M16-0271

15. Tan X, Johnson S. Fecal microbiota transplantation (FMT) for *C. difficile* infection, just say 'No.' *Anaerobe*. 2019;60:102092. doi:10.1016/j.anaerobe.2019.102092

16. Wang JW, Kuo CH, Kuo FC, et al. Fecal microbiota transplantation: Review and update. *Journal of the Formosan Medical Association*. 2019;118:S23-S31.
doi:10.1016/j.jfma.2018.08.011

17. Fecal Microbiota for Transplantation: Safety Alert - Risk of Serious Adverse Events Likely Due to Transmission of Pathogenic Organisms. U.S. Food and Drug Administration; 2020.
<https://www.fda.gov/safety/medical-product-safety-information/fecal-microbiota-transplantation-safety-alert-risk-serious-adverse-events-likely-due-transmission>

18. Lexicomp Online, Pediatric and Neonatal Lexi-Drugs Online. Waltham, MA: UpToDate, Inc.
<https://online.lexi.com>.

19. Stranges PM, Hutton DW, Collins CD. Cost-Effectiveness Analysis Evaluating Fidaxomicin versus Oral Vancomycin for the Treatment of *Clostridium difficile* Infection in the United States. *Value in Health*. 2013;16(2):297-304. doi:10.1016/j.jval.2012.11.004

20. Bartsch SM, Umscheid CA, Fishman N, Lee BY. Is Fidaxomicin Worth the Cost? An Economic Analysis. *Clinical Infectious Diseases*. 2013;57(4):555-561. doi:10.1093/cid/cit346

21. Rubio-Terrés C, Aguado JM, Almirante B, et al. Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with *Clostridium difficile* infection: cost-effectiveness analysis in Spain. *Eur J Clin Microbiol Infect Dis*. 2019;38(6):1105-1111. doi:10.1007/s10096-019-03503-4

22. Prabhu VS, Dubberke ER, Dorr MB, et al. Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent *Clostridium difficile* Infection. *Clinical Infectious Diseases*. 2018;66(3):355-362. doi:10.1093/cid/cix809